Cannabinoid Encyclopedia

Focused research review

Can CBD interact with medications?

CBD can change drug exposure through its effects on metabolism and transport, and food can substantially change CBD exposure. The size and clinical meaning of an interaction depend on the CBD product, dose, route, other medicine, and person.

Updated July 2026 9 research sources Human research included

The short answer

What is the bottom line?

CBD has interaction-relevant pharmacology; there is no one-size-fits-all medication answer. 1 2 3 4

The approved source set includes human pharmacokinetic research with highly purified oral CBD, enzyme and medicine-interaction reviews, and antiseizure medication context. In one food-effect study, a high-fat meal increased CBD exposure, which is an exposure finding rather than a health benefit. 1 2 3 4

What this means: A CBD interaction question must name both substances and the exact product. Questions about prescription medicines, dose changes, or new symptoms need patient-specific guidance from the clinician or pharmacist managing those medicines. 1 2 3 4

How to read this answer: A CBD interaction question must name both substances and the exact product. Questions about prescription medicines, dose changes, or new symptoms need patient-specific guidance from the clinician or pharmacist managing those medicines. It includes 4 specific study findings from 1 source. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBD and medication interactions.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    CBD interaction evidence depends on the exact CBD formulation, dose, route, other medicine, and person. 1

  2. 2

    A high-fat meal increased exposure to a single high dose of highly purified oral CBD in a small human pharmacokinetic study. 2

  3. 3

    Exposure or enzyme findings do not predict every clinical interaction, but they make medicine-specific review important. 3

Choose your question

What CBD interaction question do you have?

The useful question names the CBD product, the other medicine, the dose, the route, and the outcome being watched.

  1. 01Reader question

    How can food change CBD exposure?

    Read the controlled pharmacokinetic study and its formulation-specific limits.

    Explore the evidence
  2. 02Reader question

    What do metabolism studies show?

    Explore enzyme and medicine-interaction context without turning it into a universal warning.

    Explore the evidence
  3. 03Reader question

    What about antiseizure medicines?

    See why co-medications and product details matter in the clinical literature.

    Explore the evidence
  4. 04Reader question

    When is clinical guidance important?

    Medication, dose-change, and symptom questions need individual context.

    Explore the evidence

Research areas

What researchers studied about CBD and medication interactions

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

CBD interacts with drug or class drug-interaction mechanisms or safety-releva...

This part of the literature focuses on CBD interacts with drug or class drug-interaction mechanisms or safety-releva.... Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 6

Human research included

Maximum plasma CBD concentration after a high-fat meal

This part of the literature focuses on Maximum plasma CBD concentration after a high-fat meal. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 1

Human research included

Terminal CBD half-life after a high-fat meal

This part of the literature focuses on Terminal CBD half-life after a high-fat meal. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 1

Human research included

Time to maximum plasma CBD concentration after a high-fat meal

This part of the literature focuses on Time to maximum plasma CBD concentration after a high-fat meal. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 1

Human research included

Total plasma CBD exposure after a high-fat meal

This part of the literature focuses on Total plasma CBD exposure after a high-fat meal. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 1

Results extracted so far

What did the studies report?

These summaries appear only when the recorded study outcome is specific enough to reproduce from the linked source. If a source has no result summary here, the result has not been extracted yet; that does not mean the study found no effect.

clinical study in people

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.

4 recorded findings

PubMed 30374683

  • In a phase 1 randomized double-blind placebo-controlled dose-escalation and food-effect trial involving healthy adult volunteers; 12 participants in the food-effect arm, researchers reported an increase in maximum plasma CBD concentration after a high-fat meal following 1500 mg once in the food-effect arm by the oral route over single-dose food-effect assessment. The recorded comparator was fasted administration. 1

    Recorded result: A high-fat meal increased CBD Cmax 4.85-fold.

  • In a phase 1 randomized double-blind placebo-controlled dose-escalation and food-effect trial involving healthy adult volunteers; 12 participants in the food-effect arm, researchers reported an increase in total plasma CBD exposure after a high-fat meal following 1500 mg once in the food-effect arm by the oral route over single-dose food-effect assessment. The recorded comparator was fasted administration. 1

    Recorded result: A high-fat meal increased CBD AUCt 4.2-fold.

  • In a phase 1 randomized double-blind placebo-controlled dose-escalation and food-effect trial involving healthy adult volunteers; 12 participants in the food-effect arm, researchers did not detect a difference in time to maximum plasma cbd concentration after a high-fat meal following 1500 mg once in the food-effect arm by the oral route over single-dose food-effect assessment. The recorded comparator was fasted administration. 1

    Recorded result: The abstract reports no food effect on tmax.

  • In a phase 1 randomized double-blind placebo-controlled dose-escalation and food-effect trial involving healthy adult volunteers; 12 participants in the food-effect arm, researchers did not detect a difference in terminal cbd half-life after a high-fat meal following 1500 mg once in the food-effect arm by the oral route over single-dose food-effect assessment. The recorded comparator was fasted administration. 1

    Recorded result: The abstract reports no food effect on terminal half-life.

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

1 source

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

7 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

Not prominent

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 1 of 9 research source could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBD and medication interactions is not one kind of study. This source set includes 5 narrative or expert reviews, 2 systematic reviews or meta-analyses, and 1 clinical study in people. 3

The recorded populations or models include people or patients (6 sources), pediatric, adolescent, or developmental context (3 sources), and healthy adult volunteers (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is drug-interaction or safety-relevant outcomes (9 sources), area under the plasma concentration-time curve (AUCt (1 source), and maximum plasma concentration (Cmax (1 source). Closely related outcome names can still describe different measurements. 5

Some source records specify doses including 1500 mg once in the food-effect arm (1 source). These are descriptions of what researchers tested, not personal dosing instructions. 6

The CBD and medication interactions source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 7

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

clinical study in people

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes, CBD and maximum plasma CBD concentration after a high-fat meal, and CBD and total plasma CBD exposure after a high-fat meal and other related questions. 1

Study type
clinical study in people
Population or model
people or patients and healthy adult volunteers
Outcome focus
drug-interaction or safety-relevant outcomes and maximum plasma concentration (Cmax and other recorded details
Dose recorded
1500 mg once in the food-effect arm
Evidence stage
mechanism-focused research and human research

narrative or expert review

Cannabidiol's impact on drug-metabolization.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

narrative or expert review

Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 3

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

narrative or expert review

Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 4

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

narrative or expert review

Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.

On this page, this source examines CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes. 5

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
drug-interaction or safety-relevant outcomes
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CBD and medication interactions should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 6

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Does CBD interact with medications?

CBD has interaction-relevant pharmacology, but the clinical meaning depends on the medicine, CBD product, dose, route, and patient context. There is no single answer for every medication. 7

Does food change CBD exposure?

In one small study of highly purified oral CBD, a high-fat meal increased maximum concentration and total exposure compared with fasting. That describes a specific product and dose, not every CBD product. 8

Are store-bought CBD products the same as prescription CBD studies?

No. Formulation, dose accuracy, route, other ingredients, and product quality can differ substantially from the highly purified oral CBD used in clinical pharmacokinetic research. 9

What should I do about CBD and a prescription medicine?

Use medicine-specific clinical guidance from the prescriber or pharmacist who knows the medication, dose, health history, and product being considered. 1

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. clinical study in people; mechanism-focused research; human research PubMed 30374683 DOI 10.1007/s40263-018-0578-5
  2. 2
    Cannabidiol's impact on drug-metabolization. narrative or expert review; evidence still limited PubMed 37541924 DOI 10.1016/j.ejim.2023.07.029
  3. 3
    Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. narrative or expert review; evidence still limited PubMed 31288397 DOI 10.3390/jcm8070989
  4. 4
    Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. narrative or expert review; evidence still limited PubMed 32918835 DOI 10.1111/epi.16674
  5. 5
    Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. narrative or expert review; evidence still limited PubMed 39854828 DOI 10.1016/j.yebeh.2024.110261
  6. 6
    Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. systematic review or meta-analysis; evidence still limited PubMed 36206805 DOI 10.1016/j.expneurol.2022.114238
  7. 7
    Memantine for autism spectrum disorder. systematic review or meta-analysis; evidence still limited PubMed 36006807 DOI 10.1002/14651858.cd013845.pub2
  8. 8
    Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. narrative or expert review; evidence still limited PubMed 39007525 DOI 10.1002/epi4.12956
  9. 9
    A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. evidence still limited PubMed 35156171 DOI 10.1007/s40263-022-00898-1
See all 9 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 36206805
  2. Cannabidiol's impact on drug-metabolization. narrative or expert review; evidence still limited / 1 linked research note PubMed 37541924
  3. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. evidence still limited / 1 linked research note PubMed 35156171
  4. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. clinical study in people; mechanism-focused research; human research / 5 linked research notes PubMed 30374683
  5. Memantine for autism spectrum disorder. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 36006807
  6. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. narrative or expert review; evidence still limited / 1 linked research note PubMed 39007525
  7. Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. narrative or expert review; evidence still limited / 1 linked research note PubMed 39854828
  8. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. narrative or expert review; evidence still limited / 1 linked research note PubMed 31288397
  9. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. narrative or expert review; evidence still limited / 1 linked research note PubMed 32918835